Legal theft of 8,909,831 shares.
Between December and end of June, 8,909,831 flooded the OS due to conversions. Had the stock price been at $1, that would have been an acceptable 1M. In 2018 up to December of 2019, only a small 155,000 shares converted. Of course at $3.00, which was admittedly a very expensive price and can't be justified from a value perspective yet, that's a good half grand of debt erased. Therefore, I have to modify Question 3 just a bit.
1) A year or so ago, there was mention of a dual listing on the Sedar stock exchange in Canada. Can you explain why that plan was dropped, and do you have any plans to do that in the future?
1A) Can you tell give us an idea of how much Cannalytics and Amercanex are contributing in revenue at this time? They aren't broken out, and I'm wondering if a rough estimate could be given as to what each one of those contributes in terms of sales in Q2.
2) In the last conference call, you said, "We're already seeing substantially improved offerings of finance that we hope to report positively on in the Q2 call." Would you be able to elaborate on that some?
3) Between July and August, there were 500,000 extra shares added to the OS. I feel like they were from conversions. And between December 31 of 2019 and June 31, 2020, the OS increased by 9 million shares due to convertible note conversions. I worry about excessive dilution at these prices, but what is your thoughts on that? Am I looking at it wrong, and how do you see the future in terms of that? Would improved financing be able to consolidate all of the outstanding notes into one, simple financing package in the future?
4) Would it be fair to say that MJ Freeway and BioTrack are direct competitors? Do you see it that way? And if so, do they win contracts because of lower pricing? It seems to me that their margins are lower, and I'm wondering if that's because they are undercutting you in price. Am I understanding that correctly? Their stock is higher than ours, and I'm wondering what your thoughts are on the reasons behind that.
5) Does Helix have plans to uplist in the future? Akerna (KERN) seems to have gotten on the Nasdaq by way of a SPAC. If so, do you have a plan, as it's my understanding that we do not currently meet the requirements? And would a reverse split ever be considered in such a plan?
6) Can you shed any light on what the sale of the guard side of Helix would mean to your bottom line, and will that be reflected in the next quarter? Do you have a projection of what your gross revenue and margins will look like at years' end without the security business?
7) How much of your revenue is recurring, and what are your recurring growth expectations?
8) In the last 8K in regard to the sale of Helix Security, it's my understanding that Invecta assumes most of its liabilities with the exception of some pending lawsuits against the company. Do I understand that correctly? It also notes that they do not assume "matters referenced in that certain letter dated January 7, 2020, from Michael P. Kane to Grant Whitus regarding a shooting at STEM School Highlands Ranch on May 7, 2019." Could you shed some light on what that's about?
9) There's a 10b5 program in place, which automatically sells insider shares over a period of time, overseen by a neutral party. Some people see those Form 4's and get the wrong message, thinking insiders don't believe in the company. They see a large amount of form 4's, even though the overall tally is small. Are you able to say how long that will continue? I understand that you should reap the fruits of your labor, but just wondering if you feel it may send the wrong messaging out there?
